|New York, NY August 11, 2015 (PRNEWSWIRE) Immune Pharmaceuticals, Inc. (“Immune”) (NASDAQ: IMNP) announced today that it plans to release its second quarter 2015 financial results on Friday August 14, 2015 after U.S. market close.
In connection with the earnings release, Immune will host its first quarterly conference call and live audio webcast at 8:00 am EDT on Monday August 17, 2015 to discuss the results, and provide an update on the Company’s progress. Please log in approximately 5-10 minutes before the event to ensure a timely connection.
For those unable to participate in the conference call or live audio webcast, the recorded webcast will be available beginning August 17th at 11:30 a.m. EDT by visiting the Company’s website at www.immunepharmaceuticals.com.
About Immune Pharmaceuticals Inc.
Immune Pharmaceuticals Inc. applies a personalized approach to treating and, developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, Bertilimumab, is in clinical development for moderate to severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. The Company recently expanded its portfolio in immuno-dermatology, topical nano-formulated Cyclosporine A (CsA) for the treatment of psoriasis and atopic dermatitis. Immune’s pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics. Other indications planned for development include Crohn’s disease, severe asthma and NASH (liver disease).
For more information, visit Immune’s website at www.immunepharmaceuticals.com
Christine J. Petraglia
Immune Pharmaceuticals, Inc.